

Casimersen

Cat. No.:	HY-132584
CAS No.:	1422958-19-7
Molecular Weight:	7584
Target:	Others
Pathway:	Others
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Casimersen

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (13.19 mM); Need ultrasonic																							
	<table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td></td> <td>1 mM</td> <td>0.1319 mL</td> <td>0.6593 mL</td> <td>1.3186 mL</td> </tr> <tr> <td></td> <td>5 mM</td> <td>0.0264 mL</td> <td>0.1319 mL</td> <td>0.2637 mL</td> </tr> <tr> <td></td> <td>10 mM</td> <td>0.0132 mL</td> <td>0.0659 mL</td> <td>0.1319 mL</td> </tr> </tbody> </table>	Preparing Stock Solutions	Solvent Concentration	Mass			1 mg	5 mg	10 mg		1 mM	0.1319 mL	0.6593 mL	1.3186 mL		5 mM	0.0264 mL	0.1319 mL	0.2637 mL		10 mM	0.0132 mL	0.0659 mL	0.1319 mL
Preparing Stock Solutions	Solvent Concentration			Mass																				
		1 mg	5 mg	10 mg																				
	1 mM	0.1319 mL	0.6593 mL	1.3186 mL																				
	5 mM	0.0264 mL	0.1319 mL	0.2637 mL																				
	10 mM	0.0132 mL	0.0659 mL	0.1319 mL																				
	Please refer to the solubility information to select the appropriate solvent.																							
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (13.19 mM); Clear solution; Need ultrasonic																							

BIOLOGICAL ACTIVITY

Description	Casimersen (SRP-4045) is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer subclass. Casimersen binds to exon 45 of dystrophin pre-mRNA, restores the open-reading frame (by skipping exon 45) resulting in the production of an internally truncated but functional dystrophin protein. Casimersen can be used for the research of Duchenne muscular dystrophy (DMD) ^[1] .
In Vitro	Exon 45 skipping is intended to allow for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 45 skipping ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Shirley M. Casimersen: First Approval. *Drugs*. 2021;81(7):875-879.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA